RU2019142694A - Композиции и способы, которые можно использовать для лечения пролиферативных заболеваний - Google Patents
Композиции и способы, которые можно использовать для лечения пролиферативных заболеваний Download PDFInfo
- Publication number
- RU2019142694A RU2019142694A RU2019142694A RU2019142694A RU2019142694A RU 2019142694 A RU2019142694 A RU 2019142694A RU 2019142694 A RU2019142694 A RU 2019142694A RU 2019142694 A RU2019142694 A RU 2019142694A RU 2019142694 A RU2019142694 A RU 2019142694A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- composition
- administered
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 28
- 239000000203 mixture Substances 0.000 title claims 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 9
- 230000002062 proliferating effect Effects 0.000 title claims 8
- 201000010099 disease Diseases 0.000 title claims 2
- 150000003839 salts Chemical class 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 230000001028 anti-proliverative effect Effects 0.000 claims 4
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims 3
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 206010073140 Clear cell sarcoma of soft tissue Diseases 0.000 claims 2
- 201000000292 clear cell sarcoma Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000000737 periodic effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 2
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 229940125497 HER2 kinase inhibitor Drugs 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102000029749 Microtubule Human genes 0.000 claims 1
- 108091022875 Microtubule Proteins 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006994 Precancerous Conditions Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 101710183280 Topoisomerase Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 208000008524 alveolar soft part sarcoma Diseases 0.000 claims 1
- 201000007696 anal canal cancer Diseases 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims 1
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 210000004688 microtubule Anatomy 0.000 claims 1
- 230000011278 mitosis Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000000498 stomach carcinoma Diseases 0.000 claims 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 239000002435 venom Substances 0.000 claims 1
- 210000001048 venom Anatomy 0.000 claims 1
- 231100000611 venom Toxicity 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046502P | 2014-09-05 | 2014-09-05 | |
| US62/046,502 | 2014-09-05 | ||
| US201462082236P | 2014-11-20 | 2014-11-20 | |
| US62/082,236 | 2014-11-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017111204A Division RU2711500C2 (ru) | 2014-09-05 | 2015-09-04 | Композиции и способы, которые можно использовать для лечения пролиферативных заболеваний |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2019142694A true RU2019142694A (ru) | 2020-02-26 |
Family
ID=55436479
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019142694A RU2019142694A (ru) | 2014-09-05 | 2015-09-04 | Композиции и способы, которые можно использовать для лечения пролиферативных заболеваний |
| RU2017111204A RU2711500C2 (ru) | 2014-09-05 | 2015-09-04 | Композиции и способы, которые можно использовать для лечения пролиферативных заболеваний |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017111204A RU2711500C2 (ru) | 2014-09-05 | 2015-09-04 | Композиции и способы, которые можно использовать для лечения пролиферативных заболеваний |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9949981B2 (https=) |
| EP (1) | EP3189036B1 (https=) |
| JP (2) | JP6574245B2 (https=) |
| KR (1) | KR20170045748A (https=) |
| CN (2) | CN111494378A (https=) |
| AU (2) | AU2015311751B2 (https=) |
| BR (1) | BR112017004459A2 (https=) |
| CA (1) | CA2958770A1 (https=) |
| ES (1) | ES2955926T3 (https=) |
| IL (2) | IL250715B (https=) |
| MX (1) | MX382891B (https=) |
| RU (2) | RU2019142694A (https=) |
| SG (1) | SG11201701704XA (https=) |
| WO (1) | WO2016037044A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2887243C (en) | 2012-10-15 | 2024-04-09 | Epizyme, Inc. | Methods of treating cancer |
| KR20180042356A (ko) | 2015-08-24 | 2018-04-25 | 에피자임, 인코포레이티드 | 암 치료 방법 |
| CN116068187A (zh) | 2016-03-14 | 2023-05-05 | 皮尔斯生物科技有限公司 | AKT-mTOR通路蛋白的检测和量化 |
| US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
| JP7324144B2 (ja) * | 2017-02-02 | 2023-08-09 | エピザイム，インコーポレイティド | 癌処置様式 |
| WO2019071171A1 (en) * | 2017-10-05 | 2019-04-11 | The Board Of Trustees Of The University Of Illinois | Method of treating sickle cell disease |
| CN110669015A (zh) * | 2018-07-03 | 2020-01-10 | 上海喀露蓝科技有限公司 | 一种fgfr抑制剂的制备方法 |
| AU2019379179A1 (en) * | 2018-11-16 | 2021-06-10 | Arqule, Inc. | Pharmaceutical combination for treatment of cancer |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| AU2020214258B2 (en) * | 2019-01-29 | 2025-08-28 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | AKT inhibitor |
| US20220184147A1 (en) * | 2019-03-04 | 2022-06-16 | Northwestem University | Bacterial enzymatic conversion of anthracycline chemotherapeutics to reduce toxicity and promote diversity among the intestinal microbiota |
| WO2022053708A1 (en) * | 2020-09-14 | 2022-03-17 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of gastric adenocarcinoma |
| IL301567A (en) * | 2020-09-30 | 2023-05-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | A compound as an AKT KINASE inhibitor |
| CN112225745B (zh) * | 2020-11-16 | 2021-10-12 | 烟台大学 | 一种具有抗肿瘤活性的异片螺素类化合物、制备方法及用途 |
| EP4486390A1 (en) * | 2022-03-02 | 2025-01-08 | Terremoto Biosciences, Inc | Covalent modifiers of akt1 and uses thereof |
| IL326325A (en) * | 2023-08-04 | 2026-04-01 | Terremoto Biosciences Inc | 3H-Imidazo[5,4-B]pyridine compounds as non-covalent AKT1 modifiers and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8273754B2 (en) * | 2008-12-30 | 2012-09-25 | Arqule, Inc. | Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds |
| TWI461410B (zh) * | 2008-12-30 | 2014-11-21 | Arqule Inc | 經取代之５，６－二氫－６－苯基苯並〔f〕異喹啉－２－胺化合物類 |
| AU2010232644A1 (en) * | 2009-03-31 | 2011-10-20 | Arqule, Inc. | Substituted tetrahydropyrazolo-pyrido-azepin compounds |
| CA2785536C (en) * | 2009-12-30 | 2018-02-27 | Arqule, Inc. | Substituted imidazopyridinyl-aminopyridine compounds |
| US8609688B2 (en) | 2011-06-24 | 2013-12-17 | Arqule, Inc. | Substituted imidazopyridinyl-aminopyridine compounds |
| WO2012177852A1 (en) * | 2011-06-24 | 2012-12-27 | Arqule, Inc | Substituted imidazopyridinyl compounds |
-
2015
- 2015-09-04 SG SG11201701704XA patent/SG11201701704XA/en unknown
- 2015-09-04 RU RU2019142694A patent/RU2019142694A/ru unknown
- 2015-09-04 MX MX2017002892A patent/MX382891B/es unknown
- 2015-09-04 CN CN202010227563.XA patent/CN111494378A/zh active Pending
- 2015-09-04 BR BR112017004459A patent/BR112017004459A2/pt not_active IP Right Cessation
- 2015-09-04 JP JP2017512759A patent/JP6574245B2/ja not_active Expired - Fee Related
- 2015-09-04 WO PCT/US2015/048520 patent/WO2016037044A1/en not_active Ceased
- 2015-09-04 RU RU2017111204A patent/RU2711500C2/ru active
- 2015-09-04 CN CN201580060093.XA patent/CN107074769B/zh not_active Expired - Fee Related
- 2015-09-04 US US14/845,795 patent/US9949981B2/en active Active
- 2015-09-04 AU AU2015311751A patent/AU2015311751B2/en not_active Ceased
- 2015-09-04 CA CA2958770A patent/CA2958770A1/en not_active Abandoned
- 2015-09-04 ES ES15838638T patent/ES2955926T3/es active Active
- 2015-09-04 KR KR1020177008846A patent/KR20170045748A/ko not_active Abandoned
- 2015-09-04 EP EP15838638.3A patent/EP3189036B1/en active Active
-
2017
- 2017-02-22 IL IL250715A patent/IL250715B/en active IP Right Grant
-
2019
- 2019-08-15 JP JP2019149011A patent/JP6837525B2/ja not_active Expired - Fee Related
-
2020
- 2020-06-04 AU AU2020203706A patent/AU2020203706B2/en not_active Expired - Fee Related
- 2020-08-31 IL IL277028A patent/IL277028A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017526698A (ja) | 2017-09-14 |
| JP6837525B2 (ja) | 2021-03-03 |
| BR112017004459A2 (pt) | 2017-12-05 |
| AU2015311751B2 (en) | 2020-03-12 |
| AU2020203706B2 (en) | 2022-01-13 |
| RU2711500C2 (ru) | 2020-01-17 |
| SG11201701704XA (en) | 2017-04-27 |
| EP3189036A1 (en) | 2017-07-12 |
| AU2020203706A1 (en) | 2020-06-25 |
| US9949981B2 (en) | 2018-04-24 |
| KR20170045748A (ko) | 2017-04-27 |
| CA2958770A1 (en) | 2016-03-10 |
| US20160067260A1 (en) | 2016-03-10 |
| JP6574245B2 (ja) | 2019-09-11 |
| RU2017111204A3 (https=) | 2019-03-25 |
| IL250715A0 (en) | 2017-04-30 |
| JP2020002148A (ja) | 2020-01-09 |
| CN107074769B (zh) | 2020-04-07 |
| ES2955926T3 (es) | 2023-12-11 |
| IL250715B (en) | 2020-09-30 |
| MX382891B (es) | 2025-03-13 |
| CN111494378A (zh) | 2020-08-07 |
| WO2016037044A1 (en) | 2016-03-10 |
| EP3189036A4 (en) | 2018-04-04 |
| MX2017002892A (es) | 2017-06-06 |
| RU2017111204A (ru) | 2018-10-05 |
| EP3189036B1 (en) | 2023-07-19 |
| CN107074769A (zh) | 2017-08-18 |
| AU2015311751A1 (en) | 2017-03-09 |
| IL277028A (en) | 2020-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019142694A (ru) | Композиции и способы, которые можно использовать для лечения пролиферативных заболеваний | |
| JP2017526698A5 (https=) | ||
| US11541038B2 (en) | Combination comprising a glucocorticoid and EDO-S101 | |
| RU2668125C2 (ru) | Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат | |
| RU2017132877A (ru) | Комбинация антагониста pd-1 и эрибулина для лечения рака | |
| ES2561495T3 (es) | Régimen de tratamiento que utiliza neratinib contra cáncer de mama | |
| RU2018105655A (ru) | Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака | |
| RU2011142750A (ru) | Способ лечения путем применения комбинированной терапии | |
| JP2015517523A5 (https=) | ||
| RU2018137037A (ru) | Антинеопластические комбинации, содержащие hki-272 и винорелбин | |
| WO2019072220A1 (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| RU2014150860A (ru) | Режим дозирования pi-3 киназы | |
| ES2975294T3 (es) | Derivado de cumarina para terapia o profilaxis de un trastorno de la proliferación celular | |
| RU2014137190A (ru) | Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение | |
| WO2021063332A1 (zh) | 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途 | |
| Konopka-Filippow et al. | Pain management during radiotherapy and radiochemotherapy in oropharyngeal cancer patients: single-institution experience | |
| WO2023046060A1 (zh) | 治疗kras突变的癌症患者 | |
| CN111184863A (zh) | 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途 | |
| RU2019100713A (ru) | Композиции и способы для лечения рака | |
| RU2018119085A (ru) | Схема введения ингибитора фосфатидилинозитол-3-киназы | |
| US20210046071A1 (en) | Tetracyclic compounds and their salts, compositions, and methods for their use | |
| CN104434939B (zh) | 三七皂苷r7和冬凌草甲素减毒增效抗肿瘤药物组合物及其应用 | |
| JP2023011549A (ja) | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 | |
| US20220062294A1 (en) | Pharmaceutical compositions of tetracyclic quinolone analogs and their salts | |
| JP2023531090A5 (https=) |